PT  - JOURNAL ARTICLE
AU  - Mads A.J. Madsen
AU  - Vanessa Wiggermann
AU  - Stephan Bramow
AU  - Jeppe Romme Christensen
AU  - Finn Sellebjerg
AU  - Hartwig R. Siebner
TI  - Imaging cortical multiple sclerosis lesions with ultra-high field MRI
AID  - 10.1101/2021.06.25.21259363
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.25.21259363
4099  - http://medrxiv.org/content/early/2021/06/30/2021.06.25.21259363.short
4100  - http://medrxiv.org/content/early/2021/06/30/2021.06.25.21259363.full
AB  - Background Cortical lesions are abundant in multiple sclerosis (MS), yet difficult to visualize in vivo. Ultra-high field (UHF) MRI at 7T and above provides technological advances suited to optimize the detection of cortical lesions in MS.Purpose To provide a narrative and quantitative systematic review of the literature on UHF MRI of cortical lesions in MS.Methods A systematic search of all literature on UHF MRI of cortical lesions in MS published before September 2020. Quantitative outcome measures included cortical lesion numbers reported using 3T and 7T MRI and between 7T MRI sequences, along with sensitivity of UHF MRI towards cortical lesions verified by histopathology.Results 7T MRI detected on average 52±26% (mean ± 95% confidence interval) more cortical lesions than the best performing image contrast at 3T, with the largest increase in type II-IV intracortical lesion detection. Across all studies, the mean cortical lesion number was 17±6/patient. In progressive MS cohorts, approximately four times more cortical lesions were reported than in CIS/early RRMS, and RRMS. Superiority of one MRI sequence over another could not be established from available data. Post-mortem lesion detection with UHF MRI agreed only modestly with pathological examinations. Mean pro- and retrospective sensitivity was 33±6% and 71±10%, respectively, with the highest sensitivity towards type I and type IV lesions.Conclusion UHF MRI improves cortical lesion detection in MS considerably compared to 3T MRI, particularly for type II-IV lesions. Despite modest sensitivity, 7T MRI is still capable of visualizing all aspects of cortical lesion pathology and could potentially aid clinicians in diagnosing and monitoring MS, and progressive MS in particular. However, standardization of acquisition and segmentation protocols is needed.Competing Interest StatementMads A.J. Madsen, V.W. and J.R.C. have nothing to declare. Hartwig R. Siebner has received honoraria as speaker from Sanofi Genzyme, Denmark and Novartis, Denmark, as consultant from Sanofi Genzyme, Denmark, Lophora, Denmark, and Lundbeck AS, Denmark, and as editor-in-chief (NeuroImage: Clinical) and senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands. He has received royalties as book editor from Springer Publishers, Stuttgart, Germany and from Gyldendal Publishers, Copenhagen, Denmark. F.S.has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, H. Lundbeck A/S, Merck, Novartis, Roche and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. V.W. receives research support from the Danish Multiple Sclerosis Society. S.B. received one speaking honorary from Biogen Idec (Denmark) and reimbursement for congress participation from Biogen, Roche, Merck and Sanofi Genzyme.Funding StatementThis work was supported by the Danish Multiple Sclerosis Society [Grant numbers: A33409, A35202, A38506] and the Independent Research Fund Denmark [Grant number: 9039-00330A]. Hartwig R. Siebner holds a 5-year professorship in precision medicine at the Faculty of Health Sciences and Medicine, University of Copenhagen which is sponsored by the Lundbeck Foundation [Grant Nr. R186-2015-2138].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this systematic review, ethical approval was not neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the article is freely available from previously published papers.MSmultiple sclerosisUHFultra-high fieldCISclinically isolated syndromeRRMSrelapsing remitting multiple sclerosisCNScentral nervous systemMRImagnetic resonance imagingMOG-ADanti-MOG-IgGSPMSsecondary progressive multiple sclerosisPPMSprimary progressive multiple sclerosisEAEexperimental autoimmune encephalomyelitisDIRdouble inversion recoveryCSFcerebrospinal fluidFLAIRfluid attenuated inversion recoveryPSIRphase sensitive inversion recoveryIR-SWIETinversion recovery susceptibility weighted imaging with enhanced T2 weightingPRISMApreferred reporting items for systematic reviews and meta-analysesEDSSexpanded disability status scaleeRRMSearly relapsing remitting multiple sclerosisPMSprogressive multiple sclerosiswweightedMP2RAGEmagnetization prepared 2 rapid gradient echoNAGMnormal appearing gray matterFLASHfast low-angle shotMTRmagnetization transfer ratioWHATwhite matter attenuationSDMTsymbol digit modalities testBVMTbrief visuospatial memory testNPInull point image